Notably, ATP1A3 was reported to exert important effects in various cancers, including GBM,11 hepatoma and medulloblastoma.12, 13 Interestingly, Li et al12 indicated that ATP1A3 expression status may help predict the sensitivity of hepatocellular carcinoma (HCC) cells to bufalin (another kind of bufadienolide with pharmacological activity similar to CS‐6) treatment. Here, ATP1A3 is linked to hepatocellular carcinoma.